Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Mammalian Genome : Official Journal of the International Mammalian Genome Society|February 9, 2006
A protocol for high-throughput phenotyping, suitable for quantitative trait analysis in miceLeah C Solberg, William Valdar, Dominique Gauguier, et al.
International Journal of Radiation Oncology, Biology, Physics|May 22, 2025
HERMES: Randomized Trial of 2-Fraction or 5-Fraction Magnetic Resonance Imaging-Guided Adaptive Prostate Radiation TherapySian Cooper, Rosalyne L Westley, Katie Biscombe, et al.
The Lancet. Oncology|June 15, 2025
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trialAlison C Tree, Victoria Hinder, Andrew Chan, et al.
The New England Journal of Medicine|October 16, 2024
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate CancerNicholas van As, Clare Griffin, Alison Tree, et al.
The Lancet. Oncology|September 16, 2022
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trialAlison C Tree, Peter Ostler, Hans van der Voet, et al.
The Lancet. Oncology|September 22, 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trialDouglas H Brand, Alison C Tree, Peter Ostler, et al.
BJC Reports|November 8, 2024
Germline sequencing in men with metastatic castration-resistant prostate cancer from the BARCODE2 study reveals a wide range of pathogenic variants in DNA repair genesSarah Benafif, Ann-Britt Jones, Susan Merson, et al.
European Urology Oncology|June 26, 2025
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular SubtypesPasquale Rescigno, Maria Dolores Fenor de la Maza, Holly Tovey, et al.
Pageof 5